{"title":"狼疮临床试验和未来治疗的前景。","authors":"Leila Khalili, Wei Tang, Anca D Askanase","doi":"10.2478/rir-2023-0018","DOIUrl":null,"url":null,"abstract":"E-mail: ada20@cumc.columbia.edu; https://orcid.org/0000-0003-4597-5023 Several successful phase 3 trials and the approval of these new therapies in systemic lupus erythematosus (SLE), have resulted in increased interest in drug development in lupus.[1-3] Despite the recent approval of new therapies for SLE and lupus nephritis (LN) there is still an urgent need for advanced therapies as response rates are still in the 50%–60% range.[4–6]","PeriodicalId":74736,"journal":{"name":"Rheumatology and immunology research","volume":"4 3","pages":"109-114"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10538598/pdf/","citationCount":"0","resultStr":"{\"title\":\"Lupus clinical trials and the promise of future therapies.\",\"authors\":\"Leila Khalili, Wei Tang, Anca D Askanase\",\"doi\":\"10.2478/rir-2023-0018\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"E-mail: ada20@cumc.columbia.edu; https://orcid.org/0000-0003-4597-5023 Several successful phase 3 trials and the approval of these new therapies in systemic lupus erythematosus (SLE), have resulted in increased interest in drug development in lupus.[1-3] Despite the recent approval of new therapies for SLE and lupus nephritis (LN) there is still an urgent need for advanced therapies as response rates are still in the 50%–60% range.[4–6]\",\"PeriodicalId\":74736,\"journal\":{\"name\":\"Rheumatology and immunology research\",\"volume\":\"4 3\",\"pages\":\"109-114\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-09-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10538598/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Rheumatology and immunology research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2478/rir-2023-0018\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/9/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rheumatology and immunology research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2478/rir-2023-0018","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/9/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
Lupus clinical trials and the promise of future therapies.
E-mail: ada20@cumc.columbia.edu; https://orcid.org/0000-0003-4597-5023 Several successful phase 3 trials and the approval of these new therapies in systemic lupus erythematosus (SLE), have resulted in increased interest in drug development in lupus.[1-3] Despite the recent approval of new therapies for SLE and lupus nephritis (LN) there is still an urgent need for advanced therapies as response rates are still in the 50%–60% range.[4–6]
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
